Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microe...

Related Keywords

United States ,American ,Raj Malik ,Therapeutics Inc ,Investor Relations Corporate Communications ,Exchange Commission ,Research Triangle Park ,American Joint Committee On Cancer ,American Society Of Clinical Oncology ,Nasdaq ,Action Trial Results Demonstrate ,Immunomodulatory Effects ,Tumor Microenvironment ,Enhances Expression ,Genes Associated ,Memoryt Cells ,Increases Multiple Surrogate Immune Markers ,Chief Medical Officer ,Clinical Oncology ,Early Triple Negative Breast Cancer ,Immune Correlate Data ,Clinical Outcome ,Pathologic Complete Response ,Action Trial ,American Joint Committee ,Private Securities Litigation Reform Act ,Investor Relations ,